indicate

NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient in its Phase 1/2a trial for SNK01, an autologous natural killer (NK) cell therapy. The innovative product, designed for moderate AD, has demonstrated promising results in neuroinflammation and cognitive function during its Phase 1 safety trial. Key Points: SNK01 Efficacy: NKGen's SNK01, a cryopreserved autologous NK cell therapy, showed improvement in neuroinflammation and cognitive function in the Phase 1 dose-escalation safety trial. The therapy boasts enhanced

The Tightrope of Regulation

In a significant move at the recent G20 meeting in India, the International Monetary Fund (IMF) and the Financial Stability Board (FSB) released a joint paper outlining a framework for the global regulation of cryptocurrencies. While the proposals mostly tread familiar territory, what’s new is their conviction in crypto’s unstoppable growth and success. A flurry of optimism greeted the G20’s endorsement of the report because it advocates that countries don’t ban crypto. Hidden in its text, however, are some worrying signs. For example, on the first page, they state, “Widespread

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating

Don’t Fight the Fed

By the time most people read this Jerome Powell, chair of the Board of Governors of the US Federal Reserve System will have given his yearly speech at Jackson Hole, Wyoming. The speech details his financial outlook for the US and dictates whether crypto, along with most other markets, will pump or dump. Each year the Federal Reserve Bank of Kansas City holds a symposium at Jackson Hole in Grand Teton National Park that attracts central bankers, economists, and policymakers from around the world. The 2022 symposium will open on